Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chun-Yen Lin

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Open Forum Infectious Diseases|December 30, 2020
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|May 24, 2025
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus RegistryPing-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, et al.
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in TaiwanChi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in TaiwanChing-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Infectious Diseases and Therapy|December 30, 2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in TaiwanPin-Nan Cheng, Lein-Ray Mo, Chun-Ting Chen, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Open Forum Infectious Diseases|December 30, 2020
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|May 24, 2025
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus RegistryPing-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, et al.
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in TaiwanChi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in TaiwanChing-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Infectious Diseases and Therapy|December 30, 2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in TaiwanPin-Nan Cheng, Lein-Ray Mo, Chun-Ting Chen, et al.
Pageof 24